Publications

Nature communications

Author Correction: Reversal of pre-existing NGFR-driven tumor and immune therapy resistance.

07-02-2023

Melanoma research

MeVa2.1.dOVA and MeVa2.2.dOVA: two novel BRAFV600E-driven mouse melanoma cell lines to study tumor immune resistance.

01-02-2023

Cancers

Adjuvant BRAF-MEK Inhibitors versus Anti PD-1 Therapy in Stage III Melanoma: A Propensity-Matched Outcome Analysis.

07-01-2023

Annals of surgical oncology

Is a History of Optimal Staging by Sentinel Lymph Node Biopsy in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?

01-01-2023

BMC cancer

Conversion of unresponsiveness to immune checkpoint inhibition by fecal microbiota transplantation in patients with metastatic melanoma: study protocol for a randomized phase Ib/IIa trial.

30-12-2022

The New England journal of medicine

Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.

08-12-2022

Melanoma research

Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors.

01-12-2022

Data in brief

Dataset of a retrospective multicenter cohort study on characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis.

01-12-2022

JAMA oncology

Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma.

01-12-2022

Cancers

Systemic Therapy in Advanced Nodular Melanoma versus Superficial Spreading Melanoma: A Nation-Wide Study of the Dutch Melanoma Treatment Registry.

19-11-2022

European journal of cancer (Oxford, England : 1990)

Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study.

01-11-2022

Nature medicine

Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome.

01-11-2022

European journal of cancer (Oxford, England : 1990)

Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study.

01-11-2022

NEJM evidence

Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma.

01-11-2022

JCO oncology practice

End-of-Life Use of Systemic Therapy in Patients With Advanced Melanoma: A Nationwide Cohort Study.

01-10-2022

Journal of translational medicine

Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy).

04-09-2022

JCO precision oncology

BRAF and NRAS Mutation Status and Response to Checkpoint Inhibition in Advanced Melanoma.

01-09-2022

Annals of oncology : official journal of the European Society for Medical Oncology

Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study.

01-09-2022

Immuno-oncology technology

MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma: a phase I/IIa clinical trial.

01-09-2022

Clinica chimica acta; international journal of clinical chemistry

Diagnostic performance of early increase in S100B or LDH as outcome predictor for non-responsiveness to anti-PD-1 monotherapy in advanced melanoma.

01-08-2022

Annals of surgical oncology

Correction to: Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC).

01-08-2022

BJU international

Cytoreductive nephrectomy and exposure to sunitinib - a post hoc analysis of the Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME) trial.

01-07-2022

Journal for immunotherapy of cancer

Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma.

01-07-2022

Journal for immunotherapy of cancer

Dendritic cell-mediated cross presentation of tumor-derived peptides is biased against plasma membrane proteins.

01-07-2022

Annals of surgical oncology

Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC).

01-06-2022

Nature medicine

Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial.

01-06-2022

Journal of translational medicine

The "Great Debate" at Melanoma Bridge 2021, December 2nd-4th, 2021.

10-05-2022

European journal of cancer (Oxford, England : 1990)

Response to immune checkpoint inhibitors in acral melanoma: A nationwide cohort study.

01-05-2022

British journal of cancer

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF^V600-mutant advanced melanoma patients: a propensity-matched survival analysis.

01-05-2022

Science translational medicine

Addition of interleukin-2 overcomes resistance to neoadjuvant CTLA4 and PD1 blockade in ex vivo patient tumors.

27-04-2022

European journal of cancer (Oxford, England : 1990)

Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.

01-04-2022

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma.

01-04-2022

JAMA surgery

Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma.

01-04-2022

International journal of cancer

The unfavorable effects of COVID-19 on Dutch advanced melanoma care.

01-03-2022

Trials

Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced uveal melanoma (CHOPIN): study protocol for a phase Ib/randomized phase II trial.

13-02-2022

European journal of cancer (Oxford, England : 1990)

Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis.

01-02-2022

Journal of the European Academy of Dermatology and Venereology : JEADV

Survival of stage IV melanoma in Belgium and the Netherlands.

01-02-2022

Annals of oncology : official journal of the European Society for Medical Oncology

Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006.

01-02-2022

Cancer cell

Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance.

10-01-2022

European urology open science

Primary Renal Tumour Response in Patients Treated with Nivolumab and Ipilimumab for Metastatic Renal Cell Carcinoma: Real-world Data Assessment.

01-01-2022

Nature communications

Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma.

22-12-2021

Current oncology (Toronto, Ont.)

Phase Ib Study of Atezolizumab Plus Interferon-α with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors.

20-12-2021

The Lancet. Oncology

mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial.

01-12-2021

European journal of cancer (Oxford, England : 1990)

Adjuvant treatment for melanoma in clinical practice - Trial versus reality.

01-11-2021

European journal of cancer (Oxford, England : 1990)

Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma.

01-11-2021

Proceedings of the National Academy of Sciences of the United States of America

Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response.

26-10-2021

Cancers

Hospital Variation in Cancer Treatments and Survival OutComes of Advanced Melanoma Patients: Nationwide Quality Assurance in The Netherlands.

11-10-2021

Clinical cancer research : an official journal of the American Association for Cancer Research

Predictive Immune-Checkpoint Blockade Classifiers Identify Tumors Responding to Inhibition of PD-1 and/or CTLA-4.

01-10-2021

Cancer immunology, immunotherapy : CII

Metabolic profiles of regulatory T cells in the tumour microenvironment.

01-09-2021

Annals of surgery

Neoadjuvant Cytoreductive Treatment With BRAF/MEK Inhibition of Prior Unresectable Regionally Advanced Melanoma to Allow Complete Surgical Resection, REDUCTOR: A Prospective, Single-arm, Open-label Phase II Trial.

01-08-2021

Author Correction: Reversal of pre-existing NGFR-driven tumor and immune therapy resistance.

MeVa2.1.dOVA and MeVa2.2.dOVA: two novel BRAFV600E-driven mouse melanoma cell lines to study tumor immune resistance.

Adjuvant BRAF-MEK Inhibitors versus Anti PD-1 Therapy in Stage III Melanoma: A Propensity-Matched Outcome Analysis.

Is a History of Optimal Staging by Sentinel Lymph Node Biopsy in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?

Conversion of unresponsiveness to immune checkpoint inhibition by fecal microbiota transplantation in patients with metastatic melanoma: study protocol for a randomized phase Ib/IIa trial.

Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.

Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors.

Dataset of a retrospective multicenter cohort study on characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis.

Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma.

Systemic Therapy in Advanced Nodular Melanoma versus Superficial Spreading Melanoma: A Nation-Wide Study of the Dutch Melanoma Treatment Registry.

Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study.

Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome.

Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study.

Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma.

End-of-Life Use of Systemic Therapy in Patients With Advanced Melanoma: A Nationwide Cohort Study.

Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy).

BRAF and NRAS Mutation Status and Response to Checkpoint Inhibition in Advanced Melanoma.

Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study.

MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma: a phase I/IIa clinical trial.

Diagnostic performance of early increase in S100B or LDH as outcome predictor for non-responsiveness to anti-PD-1 monotherapy in advanced melanoma.

Correction to: Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC).

Cytoreductive nephrectomy and exposure to sunitinib - a post hoc analysis of the Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME) trial.

Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma.

Dendritic cell-mediated cross presentation of tumor-derived peptides is biased against plasma membrane proteins.

Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC).

Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial.

The "Great Debate" at Melanoma Bridge 2021, December 2nd-4th, 2021.

Response to immune checkpoint inhibitors in acral melanoma: A nationwide cohort study.

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis.

Addition of interleukin-2 overcomes resistance to neoadjuvant CTLA4 and PD1 blockade in ex vivo patient tumors.

Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.

Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma.

Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma.

The unfavorable effects of COVID-19 on Dutch advanced melanoma care.

Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced uveal melanoma (CHOPIN): study protocol for a phase Ib/randomized phase II trial.

Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis.

Survival of stage IV melanoma in Belgium and the Netherlands.

Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006.

Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance.

Primary Renal Tumour Response in Patients Treated with Nivolumab and Ipilimumab for Metastatic Renal Cell Carcinoma: Real-world Data Assessment.

Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma.

Phase Ib Study of Atezolizumab Plus Interferon-α with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors.

mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial.

Adjuvant treatment for melanoma in clinical practice - Trial versus reality.

Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma.

Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response.

Hospital Variation in Cancer Treatments and Survival OutComes of Advanced Melanoma Patients: Nationwide Quality Assurance in The Netherlands.

Predictive Immune-Checkpoint Blockade Classifiers Identify Tumors Responding to Inhibition of PD-1 and/or CTLA-4.

Metabolic profiles of regulatory T cells in the tumour microenvironment.

Neoadjuvant Cytoreductive Treatment With BRAF/MEK Inhibition of Prior Unresectable Regionally Advanced Melanoma to Allow Complete Surgical Resection, REDUCTOR: A Prospective, Single-arm, Open-label Phase II Trial.

This site uses cookies

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF^V600-mutant advanced melanoma patients: a propensity-matched survival analysis.